12 completed, 4 recruiting, 1 not yet recruiting. 9 Phase 2, 6 Phase 3, 2 Phase 1, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Recruiting 1 |
| Phase 3 | 6 | Completed 3, Recruiting 3 |
| Phase 1 | 2 | Completed 2 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow placebo eye drops: new trials by email Literature Review of placebo eye drops trials Research Report on placebo eye drops
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure - Glaucoma | Phase 3 | Recruiting | Glaukos Corporation | 510 | 2026-02-17 | 2026-03-30 |
| Efficacy and Safety of VMX Eye Drops for Dry Eye Disease VMX Eye Drops, placebo eye drops - Dry Eye Disease (DED) | Not applicable | Not yet recruiting | VISUfarma SpA | 76 | 2026-02-02 | 2026-01-29 |
| Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY) 0.05% atropine eye drops, 0.025% atropine eye drops, placebo eye drops - Myopia | Phase 3 | Recruiting | Ocus Innovation Ireland Limited | 234 | 2025-09-01 | 2026-02-11 |
| Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure - Glaucoma | Phase 2 | Recruiting | Glaukos Corporation | 110 | 2025-06-12 | 2026-09-17 |
| RCI001 Eye Drops 0.25% in Healthy Adult Male Participants RCI001 Eye Drops 0.25%, Placebo Eye Drops - Dry Eye | Phase 1 | Completed | Rudacure | 40 | 2024-10-28 | 2026-06-11 |
| The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression Atropine sulfate eye drops 0.01%, Atropine sulfate eye drops 0.02%, Placebo eye drops - Myopia, Myopia Progression | Phase 3 | Recruiting | Oupushifang Pharmaceutical Technology Co., Ltd. | 606 | 2024-06-15 | 2024-12-24 |
| A Study of TRS01 in Participants With Post-surgical Ocular Inflammation TRS01 eye drops, Placebo eye drops - Post Surgical Ocular Inflammation | Phase 1 / Phase 2 | Completed | Tarsier Pharma | 37 | 2020-02-01 | 2021-10-14 |
| Atropine for Preventing Ventilator-Associated Pneumonia Atropine, Placebo - Ventilator-Associated Pneumonia | Phase 2 | Completed | Universidade de Passo Fundo | 40 | 2015-02-01 | 2016-03-10 |
| Dose-Ranging Study of the Bimatoprost Ocular Insert Bimatoprost, Timolol 0.5%, Placebo Ocular Insert - Primary Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | ForSight Vision5, Inc. | 156 | 2015-01-19 | 2020-06-04 |
| Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension Bimatoprost, Timolol 0.5%, Placebo Eye Drops - Primary Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | ForSight Vision5, Inc. | 169 | 2013-10-23 | 2018-04-20 |
| Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy COLIRIOBCN070660, Placebo, Brimonidine - Diabetic Retinopathy | Phase 2 / Phase 3 | Completed | BCN Peptides | 450 | 2013-02-01 | 2016-01-12 |
| Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy 2304 Eye Drops High Dose, 2304 Eye Drops Low Dose, Placebo Eye Drops - Diabetic Macular Edema | Phase 2 | Completed | Fovea Pharmaceuticals SA | 267 | 2011-05-01 | 2012-08-23 |
| Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea rebamipide 2% ophthalmic suspension, placebo eye drops - Keratoconjunctivitis Sicca, Dry Eye | Phase 2 | Completed | Kubota Vision Inc. | 116 | 2010-02-01 | 2012-01-11 |
| Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye rebamipide 2% ophthalmic suspension, placebo eye drops - Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 2 | Completed | Kubota Vision Inc. | 220 | 2009-12-01 | 2012-01-11 |
| A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Gatifloxacin 0.5% eye drops, placebo eye drops - Bacterial Conjunctivitis | Phase 3 | Completed | Allergan | 859 | 2008-02-01 | 2019-04-23 |
| A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin Brinzolamide 1% ophthalmic solution (Azopt), Placebo eye drops, Latanoprost 0.005% ophthalmic solution (Xalatan) - Glaucoma | Phase 4 | Completed | Alcon Research | 86 | 2007-10-01 | 2014-01-13 |
| A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Gatifloxacin 0.5% eye drops, placebo eye drops - Bacterial Conjunctivitis | Phase 3 | Completed | Allergan | 578 | 2007-08-01 | 2011-11-30 |
Dry Eye Syndromes (4) · Glaucoma (4) · Glaucoma, Open-Angle (4) · Ocular Hypertension (4) · Conjunctivitis, Bacterial (2) · Keratoconjunctivitis Sicca (2) · Myopia (2) · Diabetic Retinopathy (1) · Eye Diseases (1) · Inflammation (1) · Pain (1) · Pneumonia (1) · Pneumonia, Ventilator-Associated (1)
Allergan (2) · ForSight Vision5, Inc. (2) · Glaukos Corporation (2) · Kubota Vision Inc. (2) · Alcon Research (1) · BCN Peptides (1) · Fovea Pharmaceuticals SA (1) · Ocus Innovation Ireland Limited (1) · Oupushifang Pharmaceutical Technology Co., Ltd. (1) · Rudacure (1) · Tarsier Pharma (1) · Universidade de Passo Fundo (1) · VISUfarma SpA (1)
United States (11) · Italy (3) · Spain (3) · France (2) · Germany (2) · Poland (2) · United Kingdom (2) · Albania (1) · Australia (1) · Belgium (1) · China (1) · Czechia (1) · Denmark (1) · India (1) · Israel (1)
Michelle Chen, PhD (2) · Anna R Bigioni (1) · Annegret Dahlmann-Noor, PhD (1) · Ian CK Wong, Professor (1) · Luis G. Vargas, MD (1) · Nancy Boman, MD, PhD (1) · Ningli Wang, Postdoctoral (1) · Pascale Massin, MD (1) · Ryo Kubota, MD, PhD (1) · SeungHwan Lee, M.D., Ph.D. (1)
PMID 25244402, PMID 28663190, PMID 28785768, PMID 35076329
2019 (1), 2023 (1)